Skip to main content
Clinical Trials/TCTR20200727001
TCTR20200727001CompletedPhase 3

EFFICACY OF RUESI DADTON ON MILD COGNITIVE IMPAIRMENT: A RANDOMIZED CONTROL TRIA

-0 sites71 target enrollmentStarted: July 27, 2020Last updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
-
Enrollment
71

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
50 Years to 80 Years (—)
Sex
All

Inclusion Criteria

  • Age between 50-80 year
  • - Ability to read write hearing, speaking and communication in Thai language
  • - Body mass index at low to moderate risk (19 - 27.5 kg/m2)
  • - Complaint cognition more than normal in the same age or compare with the past
  • - MMSE scores less than 24 points
  • - MoCA) scores less than 26 points
  • - Diagnosed from neurologist that amnestic-MCI

Exclusion Criteria

  • - Diagnosed with dementia
  • - History or diagnosis with cardiovascular disease
  • - Neurological disease or mental symptoms
  • - Blood pressure more than 160/100 mmHg
  • - History of alcoholism or drugs addiction
  • - Spine problems such as scoliosis, spine trauma, and disc herniation
  • - Knee pain (VAS at least 8)
  • - Cannot sit in a cross position
  • - Severe accidents in the prior 3 months
  • - History of brain accident or brain injury
  • - Continue regular exercise within the prior 2 years ( 30 min/day or over, 3 days/week or over)
  • - Intent to exercise that related to Ruesi Dadton, Tai Chi, Yoga, or Chi-Qong within three months

Investigators

Sponsor
-

Similar Trials